Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-16

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dietary intervention study in healthy young adult males to evaluate concentration of flavanol metabolites in plasma and urine after single acute intakes of methylxanthines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes

NCT03526094

Healthy

COMPLETED NA

Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans

NCT03201822

Healthy

COMPLETED NA

Biomarker-estimated Flavanol Intake in Davis (FID)

NCT06086145

Healthy Diet Adults

RECRUITING

Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1

NCT02447770

Healthy

COMPLETED NA

Effect of Phytochemicals on Aspects of Cognitive Performance

NCT02167750

Cognitive Performance

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Flavonoids, including the sub groups of Flavanols (F) are plant-derived compounds commonly present in the human diet. Examples of F-containing foods and beverages are apples, chocolate, tea, wine, berries, pomegranate and nuts. The consumption of F-containing foods and beverages has been associated with improvements in cardiovascular health. In this context, there exists a great interest in describing the absorption, metabolism and excretion of F in humans, as it is thought that F-derived metabolites present in circulation are the mediators of F-beneficial effects in humans. Recently, the investigators described a series of F-derived metabolites in circulation that are present after the consumption of a single acute intake amount of F in humans as well as F-metabolites derived from the metabolic activity of the gut microbiome. A key question, however, is if the metabolites the investigators observed after a single acute feeding are the same as those that occur in individuals who consume F-rich diets on a regular basis. Studies investigating the metabolism of numerous other xenobiotics have shown that the profile of metabolites can greatly vary over time, as well as with the amount of the xenobiotic ingested. In this context, the investigators submit it is important to assess whether or not there are food matrix-dependent effects on the levels and profile of F-derived metabolites in humans. The investigators suggest the information that will be obtained from the outlined work will be particularly timely given ongoing discussion concerning the possible generation of dietary recommendations for F-rich foods and increasing interest in the putative health effects of F intake in humans.

Following the beginning of the trial, an advanced method to analyze cocoa flavanols was accredited by AOAC International as a First Action Official Method of Analysis https://doi.org/10.1093/jaoacint/qsaa132). This updated method relies on a reference material (RM8403) recently standardized and made commercially available by the U.S. National Institute of Standards and Technology. While the actual cocoa flavanol content of our intervention remained unchanged throughout the trial, the application of this new analytical method led to expected changes in how the total cocoa flavanol content is now reported. Applying AOAC 2020.05/RM8403 to our intervention, the total cocoa flavanol content of select arms in our trials have been updated accordingly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Dietary intervention study in healthy young adult males

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CF Control

CF Control: 587 mg of cocoa flavanols (101 mg epicatechin), \<1 mg caffeine and \<1 mg theobromine

Group Type ACTIVE_COMPARATOR

CF Control

Intervention Type OTHER

CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine

CF-Theobromine

CF-Theobromine: 575 mg of cocoa flavanols (102 mg epicatechin), 11 mg caffeine and 93 mg theobromine

Group Type EXPERIMENTAL

CF-Theobromine

Intervention Type OTHER

CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine

CF-Caffeine

CF-Caffeine: 587 mg of cocoa flavanols (101 mg epicatechin), 112 mg caffeine and \<1 mg theobromine(Experimental)

Group Type EXPERIMENTAL

CF-Caffeine

Intervention Type OTHER

CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CF Control

CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine

Intervention Type OTHER

CF-Theobromine

CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine

Intervention Type OTHER

CF-Caffeine

CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No prescription medications
* BMI 18.5 - 29.9 kg/m2
* Weight ≥ 110 pounds
* previously consumed cocoa, peanut, parsley, celery and chamomile products with no adverse reactions

Exclusion Criteria

* Adults unable to consent
* Prisoners
* Non-English speaking\*
* BMI ≥ 30 kg/m2
* Performing vigorous physical activity (i.e. more than 6 MET; metabolic equivalence of task as defined by CDC and ACSM guidelines (http://www.cdc.gov/physicalactivity/everyone/glossary/index.html#vig-intensity; and http://www.cdc.gov/nccdphp/dnpa/physical/pdf/PA\_Intensity\_table\_2\_1.pdf ) for more than 3 days a week.
* Dietary allergies including those to nuts, cocoa and chocolate products, parsley, celery and chamomile.
* Active avoidance of coffee and caffeinated soft drinks
* Under current medical supervision
* A history of cardiovascular disease, stroke, renal, hepatic, or thyroid disease
* History of clinically significant depression, anxiety or other psychiatric condition
* History of Raynaud's disease
* History of difficult blood draws
* Indications of substance or alcohol abuse within the last 3 years
* Current use of herbal, plant or botanical supplements (multi-vitamin/mineral supplements are allowed)
* Blood Pressure \> 140/90 mm Hg
* GI tract disorders, previous GI surgery (except appendectomy)
* Self-reported malabsorption (e.g. difficulty digesting or absorbing nutrients from food, potentially leading to bloating, cramping or gas)
* Diarrhea within the last 3 months, or antibiotic intake within the last 3 months
* Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight loss diet or individuals following diets with significant deviations from the average diet
* Metabolic panel and cholesterol results or complete blood counts that are outside of the normal reference range and are considered clinically relevant by the study physician
* Cold, flu, or upper respiratory condition at screening
* Currently participating in a clinical or dietary intervention study

Minimum Eligible Age

25 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes